Neuronetics, Inc.

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX 11:55:28 2024-06-17 am EDT 5-day change 1st Jan Change
1.96 USD -2.97% Intraday chart for Neuronetics, Inc. -2.97% -32.41%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents CI
William Blair Upgrades Neuronetics to Outperform From Market Perform MT
Transcript : Neuronetics, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (STIM) NEURONETICS Reports Q1 Revenue $17.4M MT
Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024 CI
Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation CI
Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board CI
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21 DJ
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise MT
Neuronetics, Inc. Announces Clearance from the U.S. Food and Drug Administration for NeuroStar Advanced Therapy CI
Neuronetics, Inc. Announces 5-Year Exclusive Partnership with Transformations Care Network CI
Transcript : Neuronetics, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Earnings Flash (STIM) NEURONETICS Reports Q4 Revenue $20.3M MT
Neuronetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 CI
North American Morning Briefing : S&P 500 Futures -2- DJ
Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System CI
Top Premarket Gainers MT
Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023 CI
Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory CI
Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan CI
Neuronetics, Inc. Elevates Depression Treatment with Cutting-Edge Technology Advancements CI
Transcript : Neuronetics, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $17.9M MT
Chart Neuronetics, Inc.
More charts
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.02 USD
Average target price
7 USD
Spread / Average Target
+246.53%
Consensus
  1. Stock Market
  2. Equities
  3. STIM Stock
  4. News Neuronetics, Inc.
  5. Neuronetics : William Blair Downgrades Neuronetics to Market Perform From Outperform